Cardiac muscle conductivity

Cardiac muscle conductivity, also known as dromotropy, refers to the physiological process by which electrical impulses are propagated through the heart's specialized conduction system and the myocardium (StatPearls, 2023). This is not a single molecular target but rather a complex physiological property determined by the coordinated action of various ion channels, most notably the voltage-gated sodium channel Nav1.5 (SCN5A) and L-type calcium channels, as well as intercellular gap junctions composed of connexin proteins like Connexin 43 (PubMed, PMC4315481). High conductivity ensures that the chambers of the heart contract in a synchronized and efficient manner to maintain cardiac output. Pathological changes in conductivity are central to the development of re-entrant arrhythmias and conduction blocks, which can lead to syncope or sudden cardiac death (NIH, 2022). Pharmacological intervention typically involves Class I antiarrhythmics, which slow conduction by blocking sodium channels, or Class IV agents and beta-blockers that specifically slow conduction through the atrioventricular (AV) node (PubChem). Because this term describes a biological process rather than a specific protein or receptor, it is technically categorized as a physiological parameter rather than a discrete therapeutic target.

Other names

DromotropyConduction velocityCardiac electrical conductionMyocardial conductivity

Drugs modulate conductivity primarily by blocking voltage-gated sodium channels (reducing the rate of depolarization) or L-type calcium channels (slowing AV node conduction), or by altering the autonomic nervous system's influence on heart rate and conduction speed.